News
Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors
Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer (NSCLC) in the 2nd line after progression on a 1st-generation ALK inhibitor, crizotinib. American scientists in a phase II study focused on the efficacy of brigatinib in the treatment of patients with advanced NSCLC who had progressed on 2nd-generation ALK inhibitors.
Does olaparib improve overall survival in patients with recurrent ovarian cancer and BRCA mutation?
Olaparib, a poly(ADP-ribose) polymerase (PARP) enzyme inhibitor, in tablet form is indicated, among…
Trazodone in the Treatment of Depressive Disorder – A Case Study
Presented by MUDr. Sylva Racková, Ph.D. Psychiatric Clinic, Plzeň
Hydrotherapy in the Treatment of Non-Healing Wounds
For the treatment of wounds, it is crucial how they are managed during the cleaning and granulation…
International Recommendations for COVID-19 Vaccination in People with Bleeding Disorders
At the end of December 2020, international guidelines for COVID-19 vaccination in people with…
COVID-19: Specifics of Care for Individuals with Congenital Bleeding Disorders
The COVID-19 pandemic has significantly impacted nearly all medical fields. Alongside direct care…
Invasive Pulmonary Aspergillosis – A Common Accompanying Infection in Patients with Severe or Critical Course of COVID-19
Findings based on a literature review conducted and published in September 2020 show the occurrence…
Trifluridine/Tipiracil in the 3rd Line Treatment of mCRC − Case Study
The following case study describes the treatment of a patient with metastatic colorectal cancer…
Atectura® and Enerzair®: new fixed dual and triple combination in the treatment of bronchial asthma
In mid-2020, the European Commission approved two new fixed combinations of drugs by Novartis for…
Recent Advances in Physiotherapy for Hemophiliacs
Physiotherapy specifically focuses on movement and the movement potential of the individual, with…